Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Saccharomyces cerevisiae I-3856
- Development stage
- Unknown
- Lead developer
- Lesaffre
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Saccharomyces cerevisiae I-3856 is a proprietary, patented probiotic yeast strain developed by Lesaffre and marketed through its Gnosis by Lesaffre business unit. Registered in the French National Collection of Cultures of Microorganisms (CNCM), this strain is clinically studied for the management of irritable bowel syndrome (IBS) symptoms, particularly constipation-predominant IBS (IBS-C), where it helps alleviate abdominal pain and bloating. It is also marketed under the brand Quatreflora for supporting vaginal health, including the prevention and management of vaginal infections like vulvovaginal candidiasis and bacterial vaginosis. S. cerevisiae I-3856 works through multiple mechanisms, including modulating the gut microbiota, increasing short-chain fatty acid production, exerting anti-inflammatory effects, and co-aggregating with pathogens like Candida albicans to inhibit their adherence to epithelial cells.
- Brand names
- IbSiumQuatreflora
- Other names
- Saccharomyces cerevisiae CNCM I-3856Saccharomyces cerevisiae strain I-3856
02
Targets
FimH (Type 1 fimbrial adhesin)
Beyond the preview
Go deeper on Saccharomyces cerevisiae I-3856.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Saccharomyces cerevisiae I-3856.